Craneware And 2 Other High Growth Tech Stocks In The UK

The UK market has recently faced challenges, with the FTSE 100 index closing lower due to weak trade data from China, highlighting global economic uncertainties that have affected several sectors including commodities and finance. In this environment, identifying high-growth tech stocks like Craneware and others becomes crucial as investors seek opportunities in innovative sectors that may offer resilience against broader market volatility.

Top 10 High Growth Tech Companies In The United Kingdom

Name	Revenue Growth	Earnings Growth	Growth Rating
STV Group	13.15%	46.78%	★★★★★☆
Gaming Realms	11.57%	22.07%	★★★★★☆
Altitude Group	23.46%	27.56%	★★★★★☆
YouGov	14.29%	29.79%	★★★★★☆
Facilities by ADF	52.00%	144.70%	★★★★★☆
Redcentric	4.89%	63.79%	★★★★★☆
Windar Photonics	63.60%	126.92%	★★★★★☆
LungLife AI	100.61%	100.97%	★★★★★☆
Oxford Biomedica	21.00%	98.44%	★★★★★☆
Beeks Financial Cloud Group	22.12%	36.94%	★★★★★☆

Click here to see the full list of 46 stocks from our UK High Growth Tech and AI Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Craneware (AIM:CRW)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Craneware plc, along with its subsidiaries, specializes in developing, licensing, and supporting software solutions for the U.S. healthcare industry and has a market capitalization of £699.54 million.

Operations: Craneware generates revenue primarily from its healthcare software segment, which accounts for $189.27 million. The company focuses on providing software solutions tailored to the U.S. healthcare industry, leveraging its expertise to support various operational needs within this sector.

Craneware, a participant in the high-growth tech sector, is demonstrating robust financial and strategic progress. With an anticipated earnings growth of 25.6% annually, the company outpaces the UK market average significantly. This growth trajectory is supported by a recent strategic partnership with Microsoft Azure, enhancing its Trisus cloud platform offerings aimed at optimizing healthcare financial performance. Moreover, Craneware's commitment to innovation is evident in its R&D expenditure trends which are aligned with its revenue growth of 8.2% per year—faster than the UK market's 3.6%. These factors collectively underscore Craneware’s potential to leverage technological advancements for sustained business expansion and sector influence.

• Take a closer look at Craneware's potential here in our health report.

• Understand Craneware's track record by examining our Past report.

Capita (LSE:CPI)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Capita plc is a company that offers consulting, digital, and software solutions to both private and public sector clients in the UK and globally, with a market capitalization of approximately £345.66 million.

Operations: Capita generates revenue primarily through its Capita Experience and Capita Public Service segments, contributing £1.12 billion and £1.49 billion respectively.

Capita plc, amidst a volatile share price, has shown promising signs of recovery with its half-year sales reaching £1.24 billion, up from a previous loss, reflecting a net income turnaround to £53 million. This resurgence is underpinned by strategic extensions like the recent £135 million deal to manage the UK's smart meter communications platform until 2027—a testament to Capita's strengthening position in tech-driven public services. Furthermore, R&D investments are pivotal as they align with projected annual earnings growth of 52.1%, signaling Capita's commitment to innovation and future profitability in high-tech frameworks within the professional services sector.

• Get an in-depth perspective on Capita's performance by reading our health report here.

• Explore historical data to track Capita's performance over time in our Past section.

Genus (LSE:GNS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Genus plc is an animal genetics company with a market capitalization of approximately £1.35 billion, operating across North America, Latin America, the United Kingdom, Europe, the Middle East, Russia, Africa, and Asia.

Operations: Genus plc generates revenue primarily through its Genus ABS and Genus PIC segments, with £314.90 million and £352.50 million respectively. The company operates in various regions including North America, Latin America, and Asia among others.

Genus plc, navigating a challenging fiscal year with sales dipping to £668.8 million from £689.7 million, still maintains investor confidence through a steady dividend of 21.7 pence per share. Despite a significant net income drop to £7.9 million from last year's £33.3 million, the company is poised for recovery with projected earnings growth of 37.4% annually—outpacing the UK market's 14.2%. This optimism is bolstered by Genus’s strategic R&D focus, crucial for sustaining long-term innovation and competitiveness in biotechnology—a sector where staying ahead technologically is imperative for growth.

• Delve into the full analysis health report here for a deeper understanding of Genus.

• Evaluate Genus' historical performance by accessing our past performance report.

Key Takeaways

• Navigate through the entire inventory of 46 UK High Growth Tech and AI Stocks here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com